ObjectiveTo summarize the research progress and clinical efficacy of hepatic artery infusion chemotherapy in the treatment of colorectal cancer liver metastasis.MethodThe literatures of hepatic artery infusion chemotherapy for colorectal cancer liver metastasis were collected and reviewed.ResultsThe incidence of colorectal cancer liver metastasis was high, which affected the prognosis of patients. Surgical treatment was the preferred treatment for colorectal cancer liver metastasis. Hepatic arterial infusion chemotherapy could be used for preoperative neoadjuvant therapy and postoperative adjuvant therapy.ConclusionsHepatic arterial infusion chemotherapy is an effective local treatment for colorectal cancer liver metastasis and can be used as a supplement to surgical treatment. Compared with systemic chemotherapy, hepatic arterial infusion chemotherapy combined with systemic chemotherapy can improve the overall survival and disease-free survival, reduce the risk of intrahepatic recurrence, and improve the prognosis of patients.
Hepatocellular carcinoma (HCC) is a malignancy with high incidence and poor prognosis. Most patients with HCC are diagnosed at an intermediate-advanced stage, losing the opportunity for surgical resection. Although transcatheter arterial chemoembolization (TACE) is recommended for intermediate-advanced stage HCC, supported by evidence from multiple randomized controlled trials, its efficacy is often limited by high-risk factors such as large tumor burden, vascular tumor thrombosis, arteriovenous shunting, or infiltrative growth pattern. In recent years, accumulating evidence has established hepatic arterial infusion chemotherapy (HAIC) as an effective treatment for intermediate-advanced stage HCC, especially in patients with these high-risk features, as it can significantly enhance local tumor control and prolong survival. Recent studies and clinical practice have demonstrated that TACE and HAIC, as two effective intra-arterial therapies, possess distinct mechanisms of action. Their rational combination allows for technical complementarity, yielding a synergistic anti-tumor effect and further improving outcomes in high-risk patients with intermediate-advanced stage HCC. In this context, based on relevant literature and clinical experience, this article discusses the theoretical rationale, technical essentials, appropriate patient selection, and clinical evidence for combining TACE with HAIC in the treatment of HCC, aiming to provide references for its standardized application and wider clinical adoption.
